Immunotherapeutic Approaches for Glioblastoma Treatment

Abstract

Glioblastoma remains a challenging disease to treat, despite well‐established standard‐of-care treatments, with a median survival consistently of less than 2 years. In this review, we delineate the unique disease‐specific challenges for immunotherapies, both brain‐related and non‐brain‐related, which will need to be adequately overcome for the development of effective treatments. We also review current immunotherapy treatments, with a focus on clinical applications, and propose future directions for the field of GBM immunotherapy.